Eisai Clinical Trials

Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer’s Disease


Study Overview

NCT00478205, EU CTR 2006-004888-54
Jun 2007 - Jun 2009
Alzheimer's disease
The primary objective of this study was to compare the efficacy of donepezil sustained release (SR) 23 mg with donepezil immediate release (IR) 10 mg in the treatment of patients with moderate to severe Alzheimer's disease.

  • Males and females (aged 45 to 90 years)

  • Completed

  • Phase 3

  • United States


CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study. Clin Ther. 2010;32:1234-51.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Sample CRF
Full CSR